口服Ondansetron在狗中的生物利用性:一个交叉研究
Amanda Garrick1, Kristin Zersen1, Daniel Gustafson1
1Clinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.
Journal of veterinary pharmacology and therapeutics
|September 9, 2025
概括
在健康的狗中,口服丹塞的生物利用率非常低,估计吸收率为5.2%. 这项研究引发了对口服丹塞在犬类使用中的有效性的担忧.
科学领域:
- 兽医药理学 兽医药理学
- 药物的药理动力学 药物的药理动力学
- 狗类治疗方法 狗类治疗方法
背景情况:
- 丹塞是一种常见的抗药,用于兽医.
- 了解口服药物的生物可用性对于有效的治疗剂量至关重要.
- 有限的药理动力学数据存在于狗的口服丹塞.
研究的目的:
- 为了比较口服 (PO) 与静脉注射 (IV) 的Ondansetron在健康狗中的药理动力学.
- 在狗模型中确定Ondansetron的口服生物可用性.
- 为了评估口服丹塞特朗剂量对狗的潜在疗效.
主要方法:
- 八只健康的狗在交叉设计中接受了PO和IVondansetron (1 mg/kg).
- 用液体染色学/质谱法测量了丹塞的度.
- 计算了药理动力学参数,包括Cmax和AUC0-8h.
主要成果:
- 静脉输入的丹塞特龙显示出高血度 (AUC0-8h:1181 ± 619 ng/mL*h).
- 口服丹塞导致Cmax (22 ± 11.3 ng/ng/mL) 和AUC0-8h (61.7 ± 45.4 ng/mL*h) 较低.
- 平均口服生物利用率估计低至5.2%±2.1%.
结论:
- 在健康的狗中,ondansetron的口服生物可用性在推剂量时显著低.
- 由于吸收不良,口服Ondansetron 1 mg/kg在狗中的有效性是可疑的.
- 需要对恶心狗进行进一步的药理动力学研究,以确认临床相关性.
相关概念视频
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
170
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
170
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
126
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
126
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
261
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
261
01:13Bioavailability: Overview
3.9K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.9K
01:17Bioavailability: Overview
310
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
310
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
562
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
562